Source link : https://www.newshealth.biz/health-news/targeted-agent-promising-for-life-threatening-fetal-condition/
Treatment with the monoclonal antibody nipocalimab improved live birth outcomes and delayed or prevented fetal anemia or intrauterine transfusions in pregnancies at high risk for early-onset severe hemolytic disease of the fetus and newborn (HDFN), an open-label phase II study showed. Among 13 pregnancies — during which all mothers received intravenous nipocalimab — live birth […]
Author : News Health
Publish date : 2024-08-07 21:00:00
Copyright for syndicated content belongs to the linked Source.
inHealth